Zobrazeno 1 - 10
of 300
pro vyhledávání: '"Renchi Yang"'
Autor:
Dandan Yu, Feng Xue, Xiaofan Liu, Yunfei Chen, Rongfeng Fu, Ting Sun, Xinyue Dai, Mankai Ju, Huan Dong, Renchi Yang, Wei Liu, Lei Zhang
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 6, Pp 102554- (2024)
Background: Isolated acquired clotting factor deficiencies (ACFDs) are mainly caused by the existence of anti-factor antibodies or adsorption of clotting factors onto substances such as amyloid. Besides acquired factor (F)VIII deficiency (acquired he
Externí odkaz:
https://doaj.org/article/967e6b8beb8e4256bbedac645847ba3b
Autor:
Jia Chen, Huan Dong, Yang Li, Ting Sun, Rongfeng Fu, Xiaofan Liu, Feng Xue, Wei Liu, Yunfei Chen, Mankai Ju, Xinyue Dai, Ying Chi, Wentian Wang, Huiyuan Li, Renchi Yang, Lei Zhang, Sihan Zhou, Xiuyuan Hao
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 12, Pp 1495-1497 (2024)
Externí odkaz:
https://doaj.org/article/6c7fed0eed334a64b956e3cb352618d0
Autor:
Yunfei Chen, Yanmei Xu, Ying Chi, Ting Sun, Yuchen Gao, Xueqing Dou, Zhibo Han, Feng Xue, Huiyuan Li, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Mankai Ju, Xinyue Dai, Wentian Wang, Yueshen Ma, Zhen Song, Jundong Gu, Wei Gong, Renchi Yang, Lei Zhang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-10 (2024)
Abstract Patients with refractory immune thrombocytopenia (ITP) frequently encounter substantial bleeding risks and demonstrate limited responsiveness to existing therapies. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) present a promising
Externí odkaz:
https://doaj.org/article/5fb50871b1cd4721aeefeded6c5df3bf
Autor:
Yuchen Gao, Ying Chi, Yunfei Chen, Wentian Wang, Huiyuan Li, Wenting Zheng, Ping Zhu, Jinying An, Yanan Duan, Ting Sun, Xiaofan Liu, Feng Xue, Wei Liu, Rongfeng Fu, Zhibo Han, Yingchi Zhang, Renchi Yang, Tao Cheng, Jun Wei, Lei Zhang, Xiaomin Zhang
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract Mesenchymal stem cells (MSCs) possess potent immunomodulatory activity and have been extensively investigated for their therapeutic potential in treating inflammatory disorders. However, the mechanisms underlying the immunosuppressive functi
Externí odkaz:
https://doaj.org/article/3bc172cc2e194b8b89c4aefdeb61c25d
Autor:
Lijun Fang, Jing Sun, Yongqiang Zhao, Ming Hou, Depei Wu, Yunfei Chen, Renchi Yang, Lei Zhang
Publikováno v:
Global Medical Genetics, Vol 10, Iss 02, Pp 087-096 (2023)
Objective In this study, we aimed to evaluate the efficacy and safety of combination therapy, consisting of intravenous immunoglobulin (IVIg) and corticosteroids, in comparison to respective monotherapies in the treatment of relapsed immune thrombocy
Externí odkaz:
https://doaj.org/article/362cedc33c394be0a23b6cee0950da71
Autor:
Xiaofan Liu, Yusheng Bai, Tao Wang, Yanping Song, Feng Sun, Ruixiang Xia, Feiyue Zhu, Jun Ma, Quanyi Lu, Xu Ye, Xinrong Zhan, Linjie Li, Xinhong Guo, Shuqin Cheng, Yan Li, Zhiqiang Guo, Youhua Chen, Shenxian Qian, Ling Qin, Qing Zhang, Sunqiong Cao, Renchi Yang
Publikováno v:
Platelets, Vol 34, Iss 1 (2023)
Recombinant human TPO (rhTPO) is effective for refractory/relapsed primary immune thrombocytopenia (ITP), but optimal dosing regimen remains elusive. In this multicenter, randomized, controlled trial, a total of 282 adult ITP patients (mean age 47.3
Externí odkaz:
https://doaj.org/article/289c4f91da7940189824cb7345fad1ef
Publikováno v:
HemaSphere, Vol 7, p e66414ba (2023)
Externí odkaz:
https://doaj.org/article/942c2e96d3fa449ab9fdd123702e1135
Autor:
Xiaofan Liu, Ming Hou, Junmin Li, Jie Jin, Meijuan Huang, Ziqiang Yu, Xiaojun Xu, Xiaohui Zhang, Renchi Yang
Publikováno v:
Platelets, Vol 33, Iss 1, Pp 82-88 (2022)
This phase III, randomized, placebo-controlled study conducted in three stages (6-week, randomized, placebo-controlled stage 1; 24-week, open-label stage 2; and continuous extension stage 3) assessed the long-term efficacy and safety of eltrombopag u
Externí odkaz:
https://doaj.org/article/7bfaae16967341e18dad07aa99c497d2
Autor:
Heng Mei, Fangping Chen, Yue Han, Ming Hou, He Huang, Xiaojun Huang, Yuhua Li, Aibin Liang, Qifa Liu, Ting Niu, Jun Peng, Wenbin Qian, Yongping Song, Jianxiang Wang, Ying Wang, Depei Wu, Kailin Xu, Linhua Yang, Renchi Yang, Lei Zhang, Liansheng Zhang, Xi Zhang, Xiaohui Zhang, Weili Zhao, Weidong Han, Yu Hu, Peifang Wei
Publikováno v:
Chinese Medical Journal, Vol 135, Iss 14, Pp 1639-1641 (2022)
Externí odkaz:
https://doaj.org/article/676b50f69d9a430c903e860bcfa09607
Autor:
Wei Liu, Cuicui Lyu, Wentian Wang, Feng Xue, Lingling Chen, Huiyuan Li, Ying Chi, Yueshen Ma, Runhui Wu, Yunhai Fang, Lei Zhang, Renchi Yang
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Abstract Background The development of factor VIII (FVIII) inhibitor is a severe complication during replacement therapy for hemophilia A patients. Objectives We investigated the potential risk factors for FVIII inhibitor formation based on genome‐
Externí odkaz:
https://doaj.org/article/e6556d25e2ac44918522d9bb9033cda0